IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Average Target Price of $727.69

Key Points

• Analyst sentiment is moderately bullish: Fifteen analysts rate IDEXX Laboratories “Moderate Buy,” with nine buys and six holds. The average 12-month price target is $727.69 versus the stock’s recent price of $575.98.
• Recent analysts largely maintained positive ratings but lowered price targets, including JPMorgan at $750, Jefferies at $705, Barclays at $710, and Goldman Sachs initiating coverage with a $740 target.
• Quarterly results exceeded expectations: IDEXX reported $4.27 in earnings per share and $1.22 billion in revenue, beating estimates, while revenue increased 9.7% year over year. Institutional investors own 87.84% of the company, although a director recently sold 2,203 shares.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) have received a consensus rating of "Moderate Buy" from the fifteen analysts that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $727.69.

A number of analysts recently issued reports on IDXX shares. JPMorgan Chase & Co. dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating on the stock in a report on Friday, October 16th. Jefferies Financial Group decreased their price target on IDEXX Laboratories from $795.00 to $705.00 and set a "buy" rating on the stock in a research report on Tuesday, October 20th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Barclays lowered their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. Finally, The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They set a "buy" rating and a $740.00 price objective for the company.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.79% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Aurora Investment Managers LLC. bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at $2,442,000. National Pension Service raised its position in IDEXX Laboratories by 5.6% in the 2nd quarter. National Pension Service now owns 129,305 shares of the company's stock worth $68,071,000 after purchasing an additional 6,885 shares during the period. NewEdge Advisors LLC lifted its stake in IDEXX Laboratories by 60.9% in the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company's stock worth $8,552,000 after purchasing an additional 5,761 shares during the last quarter. Arizona State Retirement System lifted its stake in IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company's stock worth $11,988,000 after purchasing an additional 1,074 shares during the last quarter. Finally, NEOS Investment Management LLC boosted its position in IDEXX Laboratories by 12.5% during the second quarter. NEOS Investment Management LLC now owns 60,354 shares of the company's stock valued at $31,773,000 after buying an additional 6,721 shares during the period. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $575.98 on Friday. The firm has a market cap of $45.38 billion, a price-to-earnings ratio of 40.50 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories has a 52 week low of $500.61 and a 52 week high of $769.98. The firm's 50-day simple moving average is $534.16 and its two-hundred day simple moving average is $574.96.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter in the prior year, the firm earned $3.50 EPS. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts forecast that IDEXX Laboratories will post 14.81 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.